Page 1 TO E EXPERIT 1

THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application and the Application of al.

Serial No. 09/973,853

Filed: October 10, 2001

For: Aza- and Polyaza-Napthalenyl Carboxamides

Useful as HIV Integrase Inhibitors

Assistant Commissioner for Patents Washington, D.C. 20231

JAN 1 0 2002

Art Unit: 1614

Examiner: To Be Assigned

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97

Sir:

- 1. In compliance with 37 C.F.R. 1.97, submitted on the attached form herewith is a list of patents, publications or other information which are requested to be made of record in this application. This Information Disclosure Statement is not an admission that any patent, publication or other information referred to herein is "prior art" for this invention unless specifically designated as such. In accordance with 37 C.F.R. 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. 1.56(b).
- 2. In accordance with 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made.
- 3. Applicants respectfully request that the Examiner initial the attached form after reviewing the pertinence of each reference.

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on the date appearing below.

MERCK & CO., INC.

INFORMATION DISCLOSURE STATEMENT

4. Copies of the references listed on the attached form are not enclosed because they have been submitted to or cited by the Office in a related application as follows:

	RELATED APP	LICATION
U. S. SERIAL NUMBER	FILING DATE	MERCK CASE
	,	
<u> </u>		
upon which the instant application relies for an earlier filing date under 3 37 C.F.R. 1.98(d), copies of these references are not enclosed herewith		
copies will be submitted upon request.	The transfer most production, as	samona
5. In accordance with 37 C.F.R. 1.97, (check one)		
the attached information is filed within three months of the filing dat	e of the captioned case.	
the attached information is filed more than three months after the fi merits.	ling date but prior to a first	Official Action on the
the attached information is being filed more than three months after	r the filing date and after re	ceipt of the first Office

the attached information is being filed more than three months after the filing date and after receipt of the first Office Action on the merits, but before Final Action or Notice of Allowance. The enclosed authorization is therefore given to charge Deposit Account No. 13-2755 for the fee required under 37 C.F.R. 1.17(p).

the undersigned certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Statement.

the undersigned certifies that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the person signing the certification after making reasonable inquiry, was known to any individual designated under 37 C.F.R. 1.56(c) more than three months prior to the filing of the statement.

Respectfully submitted,

By: Kenneth R. Walton

Attorney For Applicant(s)

Reg. No. 32,951

MERCK & CO., INC.

Patent Dept., RY60-30

P.O. Box 2000

Rahway, N.J. 07065-0907

(732)594-3462


Date: January 10, 2002



· ·
P&T OFFICE ACKNOWLEDGEMENT
Sanith R. Water 1-10-2002
CASE NUMBER/ SERIAL NUMBER ON 1973,853
Ottober 10, 2001
Anthough Do &
EXPRESS MAIL NO.
The Patent & Trademark Office acknowledges, and has stamped hereon, the date of the receipt of the items checked below: AMENDMENT APPEAL AND FEE ASSIGNMENT BRIEF CERTIFICATE OF CORRECTION FINAL FEE LETTER REQUEST FOR F.F. LICENSE INFORMATION DISCLOSURE STATEMENT PTO 1449 & REFERENCES PETITION FOR EXTENSION OF TIME & FEE INVITATION TO CORRECT
☐ DEMAND-CHAPTER II & FEE SHEET
- F4424



P&T OFFICE ACKNOWLEDGEMENT
ATTORNEY DATE
Kenneta K. Walton 1-11-2002
CASE NUMBER/ SERIAL NUMBER
207574 197973,853
DATE FILED
(CHOBER 10, 2001
APPLICANT
EXPRESS MAIL NO.
EXPRESS MAIL NO. 1
The Patent & Trademark Office acknowledges, and has stamped hereon, the date of the receipt of the items checked below:
AMENDMENT
APPEAL AND FEE
ASSIGNMENT
☐ BRIEF
CERTIFICATE OF CORRECTIONFINAL FEE
□ LETTER
☐ BEQUEST FOR F.F. LICENSE
INFORMATION DISCLOSURE STATEMENT
☐ PTO 1449 & REFERENCES
PETITION FOR EXTENSION OF TIME & FEE
☐ INVITATION TO CORRECT
DEMAND-CHAPTER II & FEE SHEET



P&T OFFICE ACKNOWLEDGEMENT
Kennetul Walter 1-11-2002
CASE NUMBER/ SERIAL NUMBER ON 1 973, 853
OCHOBER 10, 2001
EXPRESS MAIL NO.
The Personal Paris
"The Patent & Trademark Office acknowledges and the stamped hereon, the date of the receipt of the items checked below:
AMENDMENT APPEAL AND FEE ASSIGNMENT BRIEF
CERTIFICATE OF CORRECTION FINAL FEE LETTER
DEQUEST FOR F.F. LICENSE INFORMATION DISCLOSURE STATEMENT TO 1449 & REFERENCES
PETITION FOR EXTENSION OF TIME & FEE INVITATION TO CORRECT DEMAND-CHAPTER II & FEE SHEET

F4424

A rENT Case No. 20757Y

AUG U 8 2003 EAN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants me anthony et al.

Serial No. 09/973,853 Filed: October 10, 2001

For: Aza- and Polyaza-Napthalenyl Carboxamides

. Useful as HIV Integrase Inhibitors

Assistant Commissioner for Patents Washington, D.C. 20231

Art Unit: 1614

Examiner: To Be Assigned

OCKETE 2002

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97

Sir:

- 1. In compliance with 37 C.F.R. 1.97, submitted on the attached form herewith is a list of patents, publications or other information which are requested to be made of record in this application. This Information Disclosure Statement is not an admission that any patent, publication or other information referred to herein is "prior art" for this invention unless specifically designated as such. In accordance with 37 C.F.R. 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. 1.56(b).
- 2. In accordance with 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made.
- 3. Applicants respectfully request that the Examiner initial the attached form after reviewing the pertinence of each reference.

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on the date appearing below.

MERCK & CO., INC.

INFORMATION DISCLOSURE STATEMENT

4. Copies of the references listed on the attached form are not enclosed because they have been submitted to or cited by the Office in a related application as follows:

		RELATED AP	RELATED APPLICATION		
	U. S. SERIAL NUMBER	FILING DATE	MERCK CASE		
	•	,			
upo	on which the instant application relies for an earlier filing date unde	er 35 U.S.C. 120. Therefore	, pursuant to		
37	C.F.R. 1.98(d), copies of these references are not enclosed herev	with. If this is inconvenient, a	additional		
cop	pies will be submitted upon request.		·		
	5. In accordance with 37 C.F.R. 1.97, (check one)				
	the attached information is filed within three months of the filing of	date of the captioned case.			
\checkmark	the attached information is filed more than three months after the merits.	e filing date but prior to a firs	t Official Action on the		
	the attached information is being filed more than three months at Action on the merits, but before Final Action or Notice of Allowan to charge Deposit Account No. 13-2755 for the fee required under	nce. The enclosed authoriza	eceipt of the first Office tion is therefore given		
	the undersigned certifies that each item of information contained in a communication from a foreign patent office in a counterpart to the filing of this Statement.	in this Information Disclosul foreign application not more	re Statement was cited than three months prio		
	the undersigned certifies that no item of information contained in a communication from a foreign patent office in a counterpart for signing the certification after making reasonable inquiry, was known 1.56(c) more than three months prior to the filing of the statement	reign application or, to the kr own to any individual designa	owledge of the person		
		Respectfully submitted,			
		By: Kenneth R. Walton	alton		
		•	olicant(s)		
		Reg. No. 32,951	—————		
		MERCK & CO. INC.	•		

Patent Dept., RY60-30

Rahway, N.J. 07065-0907

Date: February 4, 2002

P.O. Box 2000

(732)594- 3462



. .

P&T OFFICE ACKNOWLEDGEMENT
ATTORNEY DATE
CASE NUMBERY SERIAL NUMBER
35/15/1Y 09/913, 853
DATE FILED OCK
OCTOBE 10, 2001 FFD
APPLICANT (). 10 26 2000
EXPRESS MAIL NO.
Million .
"The Patent & Trademark Office acknowledges, and has
stamped hereon, the date of the receipt of the items checked below:
AMENDMENT O PE
APPEAL AND FEE
☐ ASSIGNMENT ☐ BRIEF FEB 1 1 2002
:: CERTIFICATE OF CORRECTION
☐ FINAL FEE
☐ REQUEST FOR F.F. LICENSE
INFORMATION DISCLOSURE STATEMENT
TP PTO 1449 & REFERENCES TP PETITION FOR EXTENSION OF TIME & FEE
"D' INVITATION TO CORRECT
☐ DEMAND-CHAPTER II & FEE SHEET

- . .



RECEIVED /F
AUG 1 2 2003

TECH CENTER 1000/1900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:

Anthony et al.

Serial No.:

09/973,853

ra 1.11.56.02

Art Unit:

1614

Docket No.:

20757Y

Examiner:

Filed:

October 10, 2001

Not Yet Assigned

For:

AZA- AND POLYAZA-NAPHTHALENYL CARBOXAMIDES

USEFUL AS INTEGRASE INHIBITORS

Assistant Commissioner for Patents Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Sir:

In compliance with 37 C.F.R. 1.97, submitted herewith on the attached form is a citation to a patent document, a copy of which is enclosed. The submission and listing of this reference is not to be construed as an admission that the reference is "prior art" with respect to the claimed invention. In accordance with 37 CFR §1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made. In addition, in accordance with 37 C.F.R. 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the statement is, or is considered to be, material to patentability as defined in 37 C.F.R. 1.56(b).

It is requested that the Examiner consider the cited reference as part of the examination of the subject application, make the reference of record, and return an initialed copy of the attached form with the next communication to Applicants.

This statement is being filed more than three months after the filing date but prior to a first Official Action on the merits. Accordingly, no fee is due. In the event a first Official Action on the merits has already been mailed, but has not yet been received, it is still believed that no fee is due, because the undersigned certifies that each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on the date appearing below.

MERCK &/CO., INC.

ring below.

Ву

Kenneth R. Walton, Reg. No. 32,951

Attorney for Applicants

Respectfully submitted,

MERCK & CO., Inc. P.O. Box 2000

Rahway, New Jersey 07065-0907

Tel.: (732) 594-3462

Date: July 10, 2002



P&T OFFICE ACKNOWLEDGEMENT

7-10-2002 Kenneth R. Walton SERIAL NUMBER 09/973,853 CASE NUMBER 20757Y DATE FILED October 10, 2001 Neville J. Anthony, et al. APPLICANT EXPRESS MAIL NO.

The Patent & Trademark Office acknowledges, and has stamped hereon, the date of the receipt of the items checked below:

... AMENDMENT

☐ APPEAL AND FEE

☐ · ASSIGNMENT

☐ BRIEF

☐ BRIEF
☐ CERTIFICATE OF CORRECTION

FINAL FEE

LETTER

☐ REQUEST FOR F.F. LICENSE

X INFORMATION DISCLOSURE STATEMENT
X PTO 1449 & REFERENCES (att. 1 ref.)

☐ PETITION FOR EXTENSION OF TIME & FEE

☐ INVITATION TO CORRECT

☐ DEMAND-CHAPTER II & FEE SHEET

F4424

IN THE CONTER 1600/2900

Applicants: Anthony, et al.

Serial No. 09/973,853

Filed: October 10, 2001

For: AZA- AND POLYAZA-NAPHTHALENYL

CARBOXAMIDES USEFUL AS INTEGRASE

INHIBITORS

Assistant Commissioner for Patents Washington, D.C. 20231

Art Unit: 1614

Examiner: Not Yet Assigned

DOCKETED

FEB 1 0 2003

LORI SCHEPISI

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97

Sir:

- 1. In compliance with 37 C.F.R. 1.97, submitted on the attached form herewith is a list of patents, publications or other information which are requested to be made of record in this application. This Information Disclosure Statement is not an admission that any patent, publication or other information referred to herein is "prior art" for this invention. In accordance with 37 C.F.R. 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. 1.56(b).
- 2. In accordance with 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made.
- 3. Applicants respectfully request that the Examiner initial the attached form after reviewing the pertinence of each reference.

DATE OF DEPOSIT	rebruary 10, 2003
ECPRESS MAL IN	EL 920633426 US
I HERENY C	STREY THE THE CORRESPONDENCE IS
DENG DENG	RITED WITH THE UNITED STATES POSTAL
ADDRESSE	AS EXPRESS MAIL TOST OFFICE TO
AN ENVELOPE	BEFORE 5 P.M. ON THE ABOVE DATE IN DIRESSED TO ASSISTANT COMMISSIONER
FOR PA	THIS, WASHINGTON D.C., 20231.
MAILED BY	Un Denotific
TATE	-111-113

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on the date appearing below.

MERCK & CO., IN	c.	
By	Date	



4. Except for Cite Nos, copies o	f the references listed on the attached f	orm are not enclosed
pecause they have been submitted to or cited by the Office	in a related application as follows:	
	RELATED A	APPLICATION
U. S. SERIAL NUMBER	FILING DATE	MERCK CASE
		PEO
		120/
		AUG 12
		TECH CENTER 16
		-11 ER 16
upon which the instant application relies for an earlier fi		
37 C.F.R. 1.98(d), copies of these references are not en	nclosed herewith. If this is inconvenien	t, additional
copies will be submitted upon request.		
5. In accordance with 37 C.F.R. 1.97, (check one)		
the attached information is filed within three months	s of the filing date of the captioned case).
the attached information is filed more than three me Office Action on the merits.	onths after the filing date but prior to the	e mailing of a first
the attached information is being filed more than the Office Action on the merits, but before the mailing of authorization is therefore given to charge Deposit A	date of a Final Action or Notice of Allow	ance. The enclosed
the undersigned certifies that each item of informat cited in any communication from a foreign patent or months prior to the filing of this Statement.		
the undersigned certifies that no item of information a communication from a foreign patent office in a communication greatent office in a communication that certification after making reason C.F.R. 1.56(c) more than three months prior to the	ounterpart foreign application, and, to the able inquiry, was known to any individu	ne knowledge of the
	Respectfully submitted,	
	By: Kenneth R. Walton	alton
	Attorney For A	
	Reg. No. 32,951	
	MERCK & CO., INC. Patent Dept., RY60-30	
	P.O. Box 2000 Rahway, N.J. 07065-09	907
	(732)594- <u>3462</u>	-
	Date: February 10, 200	03




P&T OFFICE AC	KNOWLED	GEMENT DATE
ATTORNEY Kenneth R. Walto	n	2-10-2003
CASE NUMBERV 20757Y	SERIAL NUMBE	R
October 10, 2001	OIP	E
Anthony, et al.	/ - FEB 1 0	3013 H
EL 920633426 US	Offic Schille	DEMPH and has
The Patent & Trademark stamped hereon, the dat checked below:		
☐: AMENDMENT \ ☐: APPEAL AND FEE ☐: ASSIGNMENT ☐: BRIEF	`	·
CERTIFICATE OF C	ORRECTION	
☐ REQUEST FOR F.F. INFORMATION DISC XX PTO 1449 & REFER ☐ ::PETITION FOR EXT ☐ INVITATION TO COL ☐ DEMAND-CHAPTER	CLOSURE ST ENCES (A ENSION OF T RRECT	tt. 4 refs.)
		F4424



AUG 1 2 2003
TECH CENTER 15

. Do-	
P&T OFFICE ACKNOWLEDGE	
ATTORNEY TO ACKNOWLEDGE	MENT
Renneth R. Walton	ITE ;
LIOUMBER/	-12-2003/
1 ZUITOV I SENIAL NUMBER	
DATE FILED 09/973,	353
1 - october 10, 2001	
APPLICANT	
Anthony et al.	
EXPRESS MAIL NO	•
EL 920762522 US	
The Patent & Trademark Office acknowledges stamped hereon, the date of the receipt of the checked below:	
stamped hereon, the date of the receipt of the checked below:	, and has
	items
AMENDMENT PE	
ASSIGNMENT ASSIGNMENT	~~\
ASSIGNMENT O	3 ° 1
CEPTIFIC	*
CERTIFICATE OF CORRECTION EN	.87
LETTER	N'AS
BEOLIEGT CO-	
REQUEST FOR F.F. LICENSE INFORMATION DISCLOSURE STATEMENT PTO 1449 & REFERENCES	· -
PTO 1449 & REFERENCES	
PETITION FOR EXTENSION OF TIME & FEE	[
☐ INVITATION TO CORRECT	
DEMAND CHARTE	
DEMAND-CHAPTER II & FEE SHEET	1 "
	ļ
	F4424





PATENT Case No. 2005

ES PATENT AND TRADEMARK OFFICE CENTER 16 2 2003

Applicants: Anthony et al.

Serial No. 09/973,853

Filed: October 10, 2001

For: AZA- AND POLYAZA-NAPHTHALENYL

CARBOXAMIDES USEFUL AS INTEGRASE

INHIBITORS

Assistant Commissioner for Patents Washington, D.C. 20231

Art Unit: 1614

Examiner: Not Yet Assigned

FEB 25 2003

INFORMATION DISCLOSURE STATEMENT SCREPISI UNDER 37 CFR 1.97

Sir:

- 1. In compliance with 37 C.F.R. 1.97, submitted on the attached form herewith is a list of patents, publications or other information which are requested to be made of record in this application. This Information Disclosure Statement is not an admission that any patent, publication or other information referred to herein is "prior art" for this invention. In accordance with 37 C.F.R. 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. 1.56(b).
- 2. In accordance with 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made.
- 3. Applicants respectfully request that the Examiner initial the attached form after reviewing the pertinence of each reference.

DATE OF DEPO	February 24, 2003
DUPRESS MAL	EL 920/625/5 US
HEIEN	CERTIFY THE THE CORRESPONDENCE IS
	PRINTED WITH THE LIMITED STATES POSTAL
VODE SEL	CE AS EXPRESS MAIL "POST OFFICE TO EE" BEFORE 5 PML ON THE ABOVE DATE IN
AN ERVELOP	E ABORESSED TO ASSISTANT COMMISSIONER
FOR	MATERIS, WISHINGTON, D.C., 20231.
WILED BY	
יייננט 1	2/2// OUTEDIO.

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on the date appearing below.

MERCK 8	CO., INC.
Ву	Date
	_

Computer generated form "IDS Letter" (IDS Folder), Merck & Co., Inc. 06/20/2002



INFORMATION DISCLOSURE STATEMENT

	e they have been submitted to or cited by the Office in a	reaction approaches as remember		
RELAT			TED APPLICATION	
	U. S. SERIAL NUMBER	FILING DATE	MERCK CASE	
	· · · · · · · · · · · · · · · · · · ·			
	· · · · · · · · · · · · · · · · · · ·		· · · · · · · · · · · · · · · · · · ·	
	·			
upo	on which the instant application relies for an earlier filing	date under 35 U.S.C. 120. There	fore, pursuant to	
37	C.F.R. 1.98(d), copies of these references are not enclo	sed herewith. If this is inconvenie	nt, additional	
cor	pies will be submitted upon request.	•		
	5. In accordance with 37 C.F.R. 1.97, (check one)		•	
	the attached information is filed within three months of	the filing date of the captioned cas	se.	
	the attached information is filed more than three month Office Action on the merits.	s after the filing date but prior to t	ne mailing of a first	
	the attached information is being filed more than three Office Action on the merits, but before the mailing date authorization is therefore given to charge Deposit Acco	of a Final Action or Notice of Allo	wance. The enclosed	
	the undersigned certifies that each item of information cited in any communication from a foreign patent office months prior to the filing of this Statement.			
	the undersigned certifies that no item of information con a communication from a foreign patent office in a coun person signing the certification after making reasonable C.F.R. 1.56(c) more than three months prior to the filing	terpart foreign application, and, to e inquiry, was known to any indivic	the knowledge of the	
•		Respectfully submitted	d,	
		Kenneth R. Walte	Valton	
		Attorney For		
		Reg. No. 32,951		
		MERCK & CO., INC. Patent Dept., RY60-39 P.O. Box 2000 Rabway N. L. 07065-		
		Rahway, N.J. 07065- (732)594- <u>3462</u>	——	
	••	Date: February 24, 20		



P&T OFFICE ACKNOWLEDGEMENT Kenneth R. Walton 2-24-2003 20757Y SERIAL NUMBER 09/973,853 DATE FILED October 10, 2001 APPLICANT FEB 2 4 2003 Anthony et al. EXPRESS MAIL NO. The Patent & Trademark Office and Madeges, and I stamped hereon, the date of the receipt of the items checked below: □ AMENDMENT ☐ APPEAL AND FEE ☐ ASSIGNMENT ☐ BRIEF ☐ CERTIFICATE OF CORRECTION ☐ FINAL FEE ☐ LETTER REQUEST FOR F.F. LICENSE M INFORMATION DISCLOSURE STATEMENT DIPTO 1449 & REFERENCES (att. 2 refs.) ☐ PETITION FOR EXTENSION OF TIME & FEE ☐ INVITATION TO CORRECT ☐ DEMAND-CHAPTER II & FEE SHEET

N THE UNITED STATES PATENT AND TRADEMARK OFFIC

Application Meville J. Anthony, et al.

Serial No. 09/973,853

Filed: October 10, 2001

For: AZA- AND POLYAZA-NAPHTHALENYL


CARBOXAMIDES USEFUL AS INTEGRASE

INHIBITORS

Assistant Commissioner for Patents Washington, D.C. 20231

Art Unit: 1614

Examiner: Not Yet Assigned



INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97

Sir:

- 1. In compliance with 37 C.F.R. 1.97, submitted on the attached form herewith is a list of patents, publications or other information which are requested to be made of record in this application. This Information Disclosure Statement is not an admission that any patent, publication or other information referred to herein is "prior art" for this invention. In accordance with 37 C.F.R. 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. 1.56(b).
- 2. In accordance with 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made.
- 3. Applicants respectfully request that the Examiner initial the attached form after reviewing the pertinence of each reference.

APRO A 1980

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on the date appearing below.

MERCK & CO., INC.

By Manhelloneus Date 4/2-3103

INFORMATION DISCLOSURE STATEMENT

RELATED APPLICATION			
U. S. SERIAL NUMBER	FILING DATE	MERCK CAS	
<u> </u>			
unce which the instant application relies for an obligation	data under 25 II C.C. 120. Theref	ore pursuant to	
upon which the instant application relies for an earlier filing		•	
37 C.F.R. 1.98(d), copies of these references are not enclo	sed nerewith. If this is inconvenier	nt, additional	
copies will be submitted upon request.		· · · · · · · · ·	
5. In accordance with 37 C.F.R. 1.97, (check one)	•		
the attached information is filed within three months of	the filing date of the captioned cas	e.	
the attached information is filed more than three month Office Action on the merits.	s after the filing date but prior to th	e mailing of a first	
the attached information is being filed more than three Office Action on the merits, but before the mailing date authorization is therefore given to charge Deposit Acco	of a Final Action or Notice of Allov	vance. The enclosed	
the undersigned certifies that each item of information of cited in any communication from a foreign patent office months prior to the filing of this Statement.			
the undersigned certifies that no item of information contained in this Information Disclosure Statement was cit a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, was known to any individual designated under C.F.R. 1.56(c) more than three months prior to the filing of this Statement.			
	Respectfully submitted	,	
	Kerwith R. a	alton	
	By: Kenneth R. Walto		
	Attorney For A	applicant(s)	
	Reg. No. <u>32,951</u> MERCK & CO., INC.	·	
	Patent Dept., RY60-30		
	P.O. Box 2000 Rahway, N.J. 07065-0	907	
	(732)594- <u>3462</u>		

Date: April 23, 2003



RECENTER 12 7503

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:

Anthony et al.

Serial No.:

09/973,853

Case No.: 20757Y

Art Unit:

1614

Filed:

October 10, 2001

For:

AZA- AND POLYAZA-NAPHTHALENYL

CARBOXAMIDES USEFUL AS INTEGRASE

INHIBITORS

Examiner:

Not Yet Assigned

Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450 DOCKETED JUL 15 2003 LORI SCHEPISI

INFORMATION DISCLOSURE STATEMENT

Sir:

Applicants submit the following information which they believe may be pertinent to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 C.F.R. § 1.56:

PART A

Before the filing date of the instant application, the Istituto di Ricerche di Biologia Molecolare P. Angeletti S.P.A. (IRBM) located in Italy disclosed in confidence to certain Merck employees including one or more of the applicants of the instant application certain 5,6dihydroxypyrimidine-4-carboxamides and suggested that these compounds might be

CERTIFICATE OF MAILING

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS FIRST CLASS MAIL IN AN ENVELOPE ADDRESSED TO: COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450, ON THE DATE APPEARING BELOW.

MERCK & CO., INC.

active as HTV integrase inhibitors. Representative of the earliest compounds disclosed by IRBM are 2-thienyl-substituted compounds of Formula A:

wherein R is

$$X^2$$
, wherein X^2 is H or Cl;

$$X^3$$
, wherein X^3 is CF_3 , OCH_3 , or

, wherein
$$Y^1$$
 and Y^2 are both OCH3 or both Cl;

$$Y^4$$
 Y^3 , wherein (Y^3, Y^4) is either (Cl, F) or (Cl, CH₃);

$$G^{pr}$$
 G^{pr}
 G

IRBM conducted further research on the dihydroxypyrimidine carboxamide series of compounds which led to the filing of patent applications WO 03/35076 and WO 03/35077, each of which is cited in a Form 1449 accompanying this statement (see Part B below). IRBM periodically communicated in confidence to certain Merck employees including one or more of

the applicants of the instant application on the progress of their work leading up to these patent filings, and accordingly many, though not all, of the compounds described in WO 03/35076 and WO 03/35077 were known to the applicants before the filing date of the instant application.

Before the filing date of the instant application all of the compounds of Formula A specified above and many, though not all, of the compounds described in WO 03/35076 and WO 03/35077 were tested for HIV integrase inhibition activity at Merck in the United States after their preparation in Italy.

IRBM also disclosed in confidence before the filing date of the instant application certain dihydroxypyrimidine carboxylic acids as viral polymerase inhibitors, especially as inhibitors of the hepatitis C virus polymerase enzyme. These compounds are described in WO 02/06246, which is cited in the accompanying Form 1449 (see Part B below). Many of these compounds were also tested for HIV integrase inhibiting activity at Merck in the United States before the filing date of the instant application.

IRBM also prepared the following two naphthyridine compounds before the filing date of the instant application:

$$CF_3CO_2$$
 $HN+$ S H_2N H_2N O OH O

The preparation of these compounds was communicated in confidence to certain Merck employees including one or more of the applicants of the instant application before its filing date. These compounds were tested in Italy against HCV polymerase and tested against HIV integrase at Merck in the United States before the filing date of the instant application.

The subject matter developed and disclosed by IRBM and the invention claimed in the instant application were not owned by the same person or subject to an obligation of assignment to the same person at the time the invention was made.

PART B

In compliance with 37 C.F.R. 1.97, submitted herewith on the attached Form 1449 are citations to the following patent documents: US 6262055, US 6306891, US 6380249, WO

02/06246, WO 01/00578, WO 03/35076, and WO 03/35077. Copies of these documents are enclosed herewith.

PART C

U.S. Application Serial No. 10/260,029, filed June 6, 2003, is also brought to the Examiner's attention. This pending application corresponds to WO 01/00578 listed above. A copy of USSN 10/260,029 is enclosed herewith.

PART D

The subject matter disclosed and claimed in US 6306891, US 6380249, and USSN 10/260,029 was communicated in confidence to the applicants of the instant application before the filing date of the instant application. Subject matter contained in the above-cited US patents and applications and the invention claimed in the instant application were not owned by the same person or subject to an obligation of assignment to the same person at the time the invention was made.

The submissions in Parts A, B, C and D are not to be construed as admissions that any of the submitted information is "prior art" with respect to the claimed invention. In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made. In addition, in accordance with 37 C.F.R. 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that the information disclosed is, or is considered to be, material to patentability as defined in 37 C.F.R. 1.56(b).

It is requested that the Examiner consider the information set forth in Parts A, B, C and D and make it of record. It is further requested that the Examiner return an initialed copy of the attached form 1449 with the next communication to Applicants to signify that the statement has been considered and made of record.

This statement is being submitted more than three months after the filing of the instant application but before the mailing of the first Office Action on the merits. Accordingly, no fee is believed to be due.

Respectfully submitted,

By:

Kenneth R. Walton, Reg. No. 32,951

Attorney for Applicants

MERCK & CO., Inc.

P.O. Box 2000

Rahway, New Jersey 07065-0907

Tel.: (732) 594-3462

Date: July 14, 2003



AUG-1 2 2003 TEGH CENTER 1600/2900

•	
	EDGEMENT
P&T OFFICE ACK	NOWLEDGEMENT
ATTORNEY	7/14/2003
Kenneth R. Walton	SERIAL NUMBER
CASE NUMBER	
20757Y	09/973,853
DATE FILED	•
October 10, 2001	*
APPLICANT . !	
Anthony et al.	
EXPRESS MAIL NO.	
	A DE
The Patent & Trademar	k Office acknowledges, and has
stamped hereon, the de	ate of the receipt of the items
checked below:	JUL 1 7 2003 B
☐ AMENDMENT	in the same of
APPEAL AND FEE	
☐ ASSIGNMENT	W. S.
☐ BRIEF ☐ CERTIFICATE OF	CORRECTIONADE
☐ CERTIFICATE OF	COMILE
☐ FINAL FEE	
☐ LETTER ☐ REQUEST FOR F	F LICENSE
REQUEST FOR	ISCLOSURE STATEMENT
O DETITION FOR E	XI ENSION OF TIME OF
=	CORRECT
DEMAND-CHAP	TER II & FEE SHEET
D DEIM	

F4424



P&T OFFICE ACKNOWLEDGEMENT ATTORNEY

Kenneth R. Walton CASE NUMBER

4-23-03

20757Y DATE FILED

SERIAL NUMBER 09/973,853

October 10, 2001

APPLICANT

Neville J. Anthony, et al EXPRESS MAIL NO.

The Patent & Trademark Office acknowledges, and has stamped hereon, the date of the receipt of the items checked below:

- ☐ AMENDMENT
- ☐ APPEAL AND FEE
- ☐ ASSIGNMENT ☐ BRIEF
- ☐ CERTIFICATE OF CORRECT
- ☐ FINAL FEE ☐ LETTER
- ☐ REQUEST FOR F.F. LICENSE
- INFORMATION DISCLOSURE STATEMENT
- PTO 1449 & REFERENCES

 PETITION FOR EXTENSION OF TIME & FEE
- ☐ INVITATION TO CORRECT

☐ DEMAND-CHAPTER II & FEE SHEET

AUG 0 8 2003 E IN TH

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

11 0 12

Anthony et al.

Serial No.: 09/973,853

Case No.: 20757Y

Filed:

October 10, 2001

For:

Aza- and Polyaza-Napthalenyl Carboxamides Useful as

HIV Integrase Inhibitors

11

Art Unit:

1614

Examiner:

To Be Assigned

Assistant Commissioner for Patents Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Sir:

Applicants also wish to bring the following co-pending PCT applications designating the U.S. to the Examiner's attention.

Case 20758Y PCT - Appl'n No. PCT/US01/31:550, filed 10/09/01 — Anthony et al.

Case 20759Y PCT - Appl'n No. PCT/US01/42565, filed 10/09/01 — Anthony et al.

Case 20760Y PCT - Appl'n No. PCT/US01/42553, filed 10/09/01 — Zhuang et al.

Copies of these applications are enclosed herewith. Applicants hereby request that Examiner consider the above-listed co-pending cases, initial beside each to indicate that the co-pending applications have, in fact, been considered, and return a copy of the initialed page to Applicants.

Respectfully submitted,

By:

Kenneth R. Walton, Reg. No. 32,951

Attorney for Applicants

MERCK & CO., Inc.

P.O. Box 2000

Rahway, New Jersey 07065-0907

Tel.: (732) 594-3462

Date: January 11, 2002

AUG 0 8 2003

THE UNITED STATES PATENT AND TRADEMARK OFFICE CHICENTER 1

Applicants

Anthony et al.

Serial No.:

09/973,853

Case No.: 20757Y

Art Unit: DOCKETED

1614

FEB 12 2003

Filed:

October 10, 2001

Examine LUHI SCHEPISI

For:

AZA- AND POLYAZA-NAPHTHALENYL

CARBOXAMIDES USEFUL AS INTEGRASE

INHIBITORS

Not Yet Assigned

Assistant Commissioner for Patents Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Sir:

Applicants wish to bring the following co-pending applications to the Examiner's

Case 20949Y

attention.

PCT Serial No. PCT/US 02/25666; Int'l Filing Date -- 13 Aug 2002

Merck & Co., Inc.

Case 20950Y

PCT Serial No. PCT/US 02/27151; Int'l Filing Date -- 13 Aug 2002

Merck & Co., Inc.

Case 20951Y

Serial No. 10/218,537, filed 14 Aug 2002

Anthony et al.

Applicants hereby request that Examiner consider the above-listed co-pending cases, initial beside each to indicate that the co-pending applications have, in fact, been considered, and return a copy of the initialed page to Applicants. Enclosed are copies of these applications as originally filed.

MAILED BY

Respectfully submitted,

By:

Kenneth R. Walton, Reg. No. 32,951

Attorney for Applicants

MERCK & CO., Inc.

P.O. Box 2000

Rahway, New Jersey 07065-0907

Tel.: (732) 594-3462

Date: February 12, 2003